Jan. 30, 2013
Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH) today announced that it has completed the previously announced underwritten public offering of 60,606,061 shares of its common stock, offered at a price of
per share. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 9,090,909 shares. The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were
. Anthera intends to use the net proceeds from this offering for general corporate purposes.
Jefferies & Company, Inc. is acting as sole book-running manager in the offering and Leerink Swann LLC is acting as co-manager. Trout Capital LLC has acted as an advisor to the Company.
The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at
. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor,
New York, NY
10022, or by telephone at 877-547-6340, or by email at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.